ADDING MULTIMEDIA Capri EGM Acquires R&D Build-to-Suit for National Resilience, a Biomanufacturing Company Contracted by the DOD, Harvard, and Moderna
Capri EGM, an investment company specializing in corporate build-to-suit and sale leaseback financing and the acquisition of income-generating life science, R&D, and logistics real estate, has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.
Latest Aithority Insights: Semtech Announces LoRaWAN Integration For Smart Paddock’s Smart Cattle Tracking Solution
Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT). Resilience also has a multi-year agreement to produce mNRA for Moderna’s Covid-19 vaccine, a strategic multi-year R&D alliance with Harvard University to develop complex medicines, and a multi-product biomanufacturing development agreement with Takeda supporting their plasma-derived medicines portfolio.
The Resilience Lab & Research build-to-suit is strategically located in North Florida’s Research and Life Science cluster near the University of Florida and the University of Florida’s Innovate Sid Martin Biotech Incubator, the #1 ranked biotech incubator globally. The property is surrounded by a variety of other symbiotic high-tech uses including bioscience and medical product development, pharma compounding, and R&D firms. The proximity to the University of Florida, a top 5 ranked public university, provides a pipeline of talent and research opportunities.
Browse The Complete News About Aithority: ISG to Publish Study On the Google Cloud Ecosystem
Capri EGM confirms that life science and R&D corporate real estate remain high conviction themes for its ongoing build-to-suit program and investment activity and believes that these types of assets are among the biggest beneficiaries of the developing macroeconomic trends. Life science real estate capital markets activity set an all-time record in 2021, with investment volumes of $18.4 billion according to Newmark. Capri EGM believes the pandemic has only increased the need for these types of assets and has highlighted their importance. As Capri EGM looks to current investment, innovation-oriented markets with leading research universities will remain areas of focus for its investment activity as it believes these markets will continue to experience strong demand from corporations interested in participating in their local ecosystems.
National Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. The company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives.
Read More About Aithority News : Orca Security Now Available in the Microsoft Azure Marketplace
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.